Close Menu

NEW YORK (GenomeWeb) – Calling current market conditions unattractive, cardiovascular disease molecular diagnostics firm CardioDx is withdrawing its planned initial public offering.

The company filed a request with the US Securities and Exchange Commission on Tuesday to withdraw its IPO, saying, "The terms currently obtainable in the public marketplace are not sufficiently attractive to the [company] to warrant proceeding with the public offering."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.